Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986224 · 1 trial · 2 indications
Part 1 only
Part 1 only
Part 1 only
| Arm | Type | Description |
|---|---|---|
| Normal Renal Function | EXPERIMENTAL | - |
| Mild Renal Impairment | EXPERIMENTAL | - |
| Moderate Renal Impairment | EXPERIMENTAL | - |
| Severe Renal Impairment | EXPERIMENTAL | - |
| End-Stage Renal Disease (ESRD) | EXPERIMENTAL | ESRD participants and are on chronic hemodialysis |
| Name | Type | Description |
|---|---|---|
| BMS-986224 | DRUG | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * BMI ≥18 and ≤ 35kg/m2 * Systolic blood pressure \>100 mmHg Exclusion Criteria: * Women of childbearing potential or women who are currently pregnant * Clin...
BMS-986224 is an investigational small molecule being developed by Bristol-Myers Squibb Company for cardiac failure. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not an approved therapy and remains under clinical evaluation for cardiovascular use.
BMS-986224 is being evaluated for cardiac failure, including myocardial failure. Its only recorded clinical study enrolled renally impaired participants, a population often studied alongside heart failure. The drug is investigational, so it has no approved use outside of clinical research.
BMS-986224 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the compound in renally impaired participants conducted in the United States.
BMS-986224 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The compound has not been approved by the FDA and remains an investigational agent for cardiac failure.
BMS-986224 has been studied in one completed Phase 1 trial, NCT03634969, titled an investigational study to evaluate experimental medication BMS-986224 in renally impaired participants. It enrolled 50 participants in the United States, included healthy volunteers, and used a controlled design without randomization or double blinding.